Pertuzumab

• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended
  2023-509923-42-00 Phase II 5 countries Medica Scientia Innovation Research S.L.
• An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl… Ended
  2023-505102-42-00 Phase III 3 countries F. Hoffmann-La Roche AG
• PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended
  2023-508411-23-00 Phase II 1 country Karolinska University Hospital
• An Extension Study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients pr… Ended
  2023-503479-79-00 Phase II 5 countries F. Hoffmann-La Roche AG
• A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos… Ended
  2023-506038-65-00 Phase II 3 countries Bolt Biotherapeutics Inc.
• A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi… Ended
  2023-506380-33-00 Phase III 3 countries F. Hoffmann-La Roche AG
• Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended
  2024-512826-26-00 Phase II 1 country Institut Gustave Roussy
• Study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patie… Ended
  2024-512050-13-00 Phase III 1 country Novartis Pharma AG
• Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a… Ended
  2023-508826-92-00 Phase I (Other) 1 country Solti Group

Showing 25–33 of 33 trials